1. Home
  2. Labeler Index
  3. Golden State Medical Supply, Inc.
  4. 51407-089
  5. Product Images: Felodipine

Product Images Felodipine

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 6 images provide visual information about the product associated with Felodipine NDC 51407-089 by Golden State Medical Supply, Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

image description - 1 formula

image description - 1 formula

51407-087-01LB.jpg - 51407 087 01LB

51407-087-01LB.jpg - 51407 087 01LB

NDC 51407-087-01 is a medication called Felodipine. This medication comes in the form of extended-release tablets, USP, with a strength of 2.5mg and is supplied in a bottle containing 100 tablets. Dosage information can be found in the package insert. Store the medication at room temperature between 20°-25°C (68°-77°F).*

51407-088-01LB.jpg - 51407 088 01LB

51407-088-01LB.jpg - 51407 088 01LB

Product: FELODIPINE Tablets, USP 5mg - 100 tablets - Extended-Release. This medicine should be taken by swallowing it whole, NOT crushed or chewed. Dosage information is provided in the package insert. Store at temperatures between 20°C-28°C. Dispense in a tight and light-resistant container as indicated by the USP. Manufactured by Yung Shin Pharmaceutical Ind. Co., Ltd. in Tainan, Taiwan. Marketed and distributed by GEMS, Inc. in Camarillo, CA, USA.*

51407-089-01LB.jpg - 51407 089 01LB

51407-089-01LB.jpg - 51407 089 01LB

Feoldipine is an extended-release medication available in 10mg tablets. The tablets should be swallowed, not chewed. The package insert should be consulted for dosage information. The manufacturer is Yung Shin Pharmaceutica Ind. Co., Ltd. and the product is packaged by GEMS, Inc. The ideal storage temperature is between 20-26°C (68-78°F).*

table 1 - table 1

table 1 - table 1

This is a table showing the mean reductions in blood pressure (in mmHg) with different doses of a medication over 8 and 4 weeks for two different studies. Placebo response has been subtracted from the values. The number of patients available for peak and trough measurements differs.*

table 2 - table 2

table 2 - table 2

This table shows the percentage of patients who experienced adverse events while taking Felodipine extended-release tablets as a monotherapy in controlled trials. The adverse events are categorized by body system, and the incidence of discontinuations is also shown. The patients were divided into four groups based on the different doses they received. Peripheral edema was the most common adverse event reported, followed by asthenia, palpitation, headache, and dizziness. Patients in titration studies may have been exposed to more than one dose level of Felodipine extended-release tablets.*

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.